.
MergerLinks Header Logo

Announced

Completed

Advent International to acquire Zentiva for €1.9bn.

Financials

Edit Data
Transaction Value£1,643m
Consideration Type-
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

generic medicines distribution

generic medicines manufacturing

generic medicines development

Pharmaceuticals

Czechia

Private

Disposal

Single Bidder

Completed

Natural

Private Equity

Synopsis

Edit

Advent International completed €1.9bn acquisition of Zentiva, an international pharmaceutical company focused on developing, manufacturing and marketing modern generic pharmaceutical products, from Sanofi, a French multinational pharmaceutical company headquartered in Paris. “Zentiva is a robust business with a highly talented workforce and we believe it has demonstrated its potential for growth. Following a comprehensive review of strategic options for our generics unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success,” said Olivier Brandicourt, Chief Executive Officer, Sanofi.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US